Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
microRNA 4288 (MIR4288)
- Target
- MIR4288
- Molecular classification
- microRNA, Non-coding RNA, Regulatory RNA, Small RNA
01
Overview
microRNA 4288 (MIR4288) is a small, non-coding RNA molecule in humans, belonging to the microRNA family. Like other miRNAs, MIR4288 regulates gene expression by binding to target messenger RNAs, typically resulting in their degradation or translational inhibition. It has been implicated in prostate cancer, where loss of MIR4288 is associated with increased metastatic and invasive potential due to upregulation of specific target genes (MMP16, ROCK1)[5]. Outside of this role, functional and therapeutic information is limited. As a regulatory molecule rather than a receptor or enzyme, MIR4288 is not a classical drug target but may be useful as a biomarker or in future RNA-based therapies.
- Other names
- hsa-mir-4288MIR4288microRNA 4288miR-4288
02
Mechanism of action
Inhibition of target gene expression via mRNA degradation or translational repression (typical for miRNAs); Specific for MIR4288: direct repression of MMP16 and ROCK1 in prostate cancer
03
Biological functions
Post-transcriptional regulation of gene expressionFine-tuning and buffering of protein outputPotential involvement in cancer cell migration/invasion suppressionOther (general functions associated with miRNAs)
04
Disease associations
Cancer (notably, deletion or reduced expression of miR-4288 is seen in prostate cancer; it directly represses genes involved in metastasis/invasion such as MMP16 and ROCK1)Other (since miRNAs have wide roles in various diseases, but specific evidence for MIR4288 is mainly cancer)
05
Safety considerations
None documented specifically for MIR4288. General challenges for miRNA-based therapies include off-target effects and delivery issues
06
Interacting drugs
None known. MicroRNAs like MIR4288 do not have identified direct drug interactions, but gene therapy or oligonucleotide-based therapeutics (antagomirs, mimics) may be used experimentally
07
Biomarkers
Loss or deletion of MIR4288 may serve as a biomarker of prostate cancer or metastatic potential
Beyond the preview
Go deeper on microRNA 4288 (MIR4288).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on microRNA 4288 (MIR4288).